Recommendations guiding physicians in biomedicalresearch involving human subjects. JAMA 1997;277:925–926. 24. Ruberg SJ: Dose response studies. II. Analysis and in- terpretation. J Biopharm Stat 1995;5:15–42. 25. Nielsen LL, Baron AD: Pharmacology of exenatide (synthetic exendin-4) for the treatment of type 2 dia-betes. Curr Opin Investig Drugs 2003;4:401–405. 26. Garber A, Marre M, Blonde L, Allavoine T, Howlett H, Lehert P, Cornes M: Influence of initial hypergly-caemia, weight and age on the blood glucose lower-ing efficacy and incidence of hypoglycaemic symp-toms with a single-tablet metformin-glibenclamidetherapy (Glucovance) in type 2 diabetes. DiabetesObes Metab 2003;5:171–179. 27. Rendell MS, Glazer NB, Ye Z: Combination therapy with pioglitazone plus metformin or sulfonylurea inpatients with Type 2 diabetes: Influence of prior an-tidiabetic drug regimen. J Diabetes Complications2003;17:211–217. 28. Willms B, Ruge D: Comparison of acarbose and met-